Navigation Links
ADVENTRX Announces Management Promotions
Date:2/4/2010

SAN DIEGO, Feb. 4 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that, effective immediately, Brian M. Culley, previously the Company's Chief Business Officer and a Senior Vice President, will serve as its Chief Executive Officer and Patrick L. Keran, previously the Company's General Counsel, will serve as its President and Chief Operating Officer.  Mr. Keran also will continue to serve as the Company's Secretary and Principal Financial and Accounting Officer.  

"The title changes we announce today are well-deserved and reflect the responsibilities and operational influence that Brian and Pat assumed some time ago," said Jack Lief, Chair of the ADVENTRX Board of Directors.  "The Board has confidence in their strategic planning and ability to execute, evidenced in part by their capital-raising success and the submission of the ANX-530 NDA, all during extremely difficult times."  

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use.  More information can be found on the Company's web site at www.adventrx.com.  

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements.  These risks and uncertainties include, but are not limited to: ADVENTRX's dependence on the success of ANX-530, and uncertainty as to whether ANX-530 will receive regulatory approval or be commercialized successfully; the potential that FDA may not accept the ANX-530 NDA for review, or that the bioequivalence data and other information included in the ANX-530 NDA may not adequately support bioequivalence with Navelbine; the potential that changes made in transferring the manufacturing process for ANX-530 may result in a lack of comparability between the commercial product and the material used in clinical trials; the potential for FDA to impose other requirements to be completed before or after approval of the ANX-530 NDA; the possibility that patent claims covering ANX-530 will not issue or, if they do, that such claims, which likely will be limited to a specific intravenous emulsion formulation of vinorelbine, will not be sufficient to preclude development of other formulations of vinorelbine by competitors; the risk of investigator bias in reporting adverse events as a result of the open-label nature of the ANX-530 bioequivalence study, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov.  

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made.  ADVENTRX does not intend to revise or update any forward-looking statement set forth in this press release to reflect events or circumstances arising after the date on which it was made.

SOURCE ADVENTRX Pharmaceuticals, Inc.

RELATED LINKS
http://www.adventrx.com

'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
3. ADVENTRX Meets Primary Endpoint in ANX-530 Marketing-Enabling Clinical Study
4. ADVENTRX Announces Completion of Patient Enrollment in Phase 2 Clinical Trial of CoFactor(R) for the Treatment of Advanced Breast Cancer
5. ADVENTRX to Present ANX-201 Preclinical Data at Keystone Symposia HIV Pathogenesis Conference
6. ADVENTRX to Present CoFactor Phase 2 Breast Cancer Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
7. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
8. ADVENTRX Presents CoFactor Data at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO)
9. ADVENTRX Announces CoFactor(R) Phase 2b Clinical Trial Overall Survival Results
10. ADVENTRX Announces Preliminary Response Rate Data From Discontinued Phase 3 Trial of CoFactor(R)
11. ADVENTRX Completes Patient Enrollment in ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... südwestlichen chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize ... der Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - ... ... ...
(Date:2/23/2017)... , Feb. 23, 2017 AcelRx ... focused on the development and commercialization of innovative ... announced that it will release fourth quarter and ... March 2nd, 2017. AcelRx management will host an ... (1:30 p.m. Pacific Time) on March 2 nd ...
(Date:2/23/2017)... , February 23, 2017 According ... by Product (X-ray Imaging Digital, Analog), MRI (Closed, Open), ... MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers) - ... studies the global market over the forecast period of ... ~USD 36.43 Billion by 2021, at a CAGR of ...
Breaking Medicine Technology:
(Date:2/24/2017)... Melbourne, Australia (PRWEB) , ... February 24, 2017 , ... ... Press AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema ... post-traumatic stress disorder and his attempts to overcome them. , Schanssema, initially unsure ...
(Date:2/24/2017)... ... 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer ... started as the Chairman of the Management Committee when IFN was originally formed in ... recruitment of investor/owners and development of the business plan. He became the first ...
(Date:2/23/2017)... ... 23, 2017 , ... Thinksport, the most award-winning sunscreen on ... of Marin. For the second year in a row, cyclists will stay protected ... are thrilled to provide our safe, non-toxic sunscreen to over 2,000 cycling enthusiasts ...
(Date:2/23/2017)... Chapel Hill, NC (PRWEB) , ... February 23, 2017 , ... ... the Platinum Sponsor for ACPA’s 74th Annual Meeting. KLS is a longtime supporter ... in 2017 as an exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, 2017, ... on “Doping in Sport: How the Culture Might Change,” in conjunction ... The symposium will be held at Pepperdine University in Malibu, California. , Sir ...
Breaking Medicine News(10 mins):